FP7 logo euThe SATURN project has received funding from the European Community's Seventh Framework Programme [FP7/2007-2013] under grant agreement n°241796

Impact of Specific Antibiotic Therapies on the Prevalence of Human Host Resistant Bacteria

Partners: Tel-Aviv Medical Centre – (TASMC)

The organisation

TASMCTel Aviv Sourasky Medical Center is a 1200-bed Tertiary care teaching hospital, serving a population of approximately 1,000,000. It is affiliated to the Sackler Faculty of Medicine, Tel-Aviv University. The Foundation for Medical Research, Infrastructure Development and Health Services is a separate legal entity established and dully registered under the Israeli law. The TASMC-FUND is authorised to perform and execute research projects in the Tel-Aviv Sourasky Medical Center whilst using its facilities.

The project SATURN will be carried out by the Division of Epidemiology. The division has as a major task to improve our understanding of the development and spread of antimicrobial resistance, and thereby to design measures and adopt strategies to combat it. The division is responsible for infection control, health care epidemiology, hospital personnel health, and statistical services. The division also includes the Laboratory for Molecular Epidemiology and Antibiotic Research. The laboratory aims are also to improve methods of identifying AMR, to understand the spread of resistance, and of improved antimicrobial treatment, including the development of new antimicrobials and anti-bacterial vaccines. Projects performed by the Division of Epidemiology have received grant support from the European Commission (MOSAR, FP6), Bi-National Israel-America Science Foundation, the Sapir Foundation, the Center for Emerging Diseases, the Chief Scientist of the Israel Ministry of Industry and Commerce, and the Chief Scientist of the Israel Ministry of Health.

Key staff involved in the project

Yehuda CarmeliYehuda Carmeli, MD, MPH, head of the Division of Epidemiology, will coordinate Workpackage 5. Dr Carmeli, has received his training in infectious diseases and in public-health at Harvard University. He has over 120 peer-reviewed publications in the area of AMR and hospital epidemiology in various journals (including JAMA, Circulation, Nature Microbiology, Archives of Internal Medicine, and Antimicrobial Agents and Chemotherapy). He serves at the editorial board of Clinical Infectious Diseases, Infection Control and Hospital Epidemiology, and Current Opinion in Infectious Diseases. He is the chair of the advisory committee to the Israeli Ministry of Health on Nosocomial Infections and Antibiotic Resistance. Dr Carmeli is a WP leader in the FP6 MOSAR project on the dissemination of antimicrobial resistance in rehabilitation centers and to the community.

Mitchell SchwaberMitchell Schwaber, MD, MSc, head of the Israeli National Center for Infection Control, Received his training in infectious diseases, Epidemiology and antibiotic resistance at Harvard Medical School, Harvard School of Public Health and The CDC. He performed many studies on antibiotic resistance in Carbapenem-resistant Enterobacteriaceae and on ESBLs. He is currently involved in infection control, and is responsible for interventional activities on limiting the spread of antibiotic resistance.
Shiri Navon-Venezia, PhD, head of the Laboratory for Molecular Epidemiology and Antibiotic Research, is a microbiologist experiences in the area of antimicrobial resistance and molecular epidemiology. Her recent work includes studies on Carbapenem-resistant Enterobacteriaceae, ESBLs, and Acinetobacter baumannii. She has extensive experience in management and administration of research projects.

Further information

The Tel Aviv Sourasky Medical Center
6 Weizmann Street
Tel Aviv 64239

Top ^